Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 200 clinical trials
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818)

platinum-based chemotherapy concurrently in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.

adenosquamous carcinoma
cancer chemotherapy
paclitaxel carboplatin
endometrioid adenocarcinoma
maintenance therapy
  • 9 views
  • 11 Oct, 2022
  • 23 locations
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.

cancer chemotherapy
KRAS
lung carcinoma
platinum-based chemotherapy
docetaxel
  • 0 views
  • 07 Oct, 2022
  • 8 locations
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

The primary objective of the study is to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

  • 4 views
  • 20 Oct, 2022
  • 270 locations
Biomarker-based Study in R/M SCCHN

This is a biomarker-driven trial that will enroll patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum-based chemotherapy

palbociclib
caries
measurable disease
atezolizumab
platinum-based chemotherapy
  • 276 views
  • 09 Dec, 2021
  • 37 locations
  • 0 views
  • 29 Oct, 2022
  • 27 locations
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

complete course of platinum-based chemotherapy and whose disease has relapsed with platinum resistance ([PRR]-HGSOC) and to determine the plasma pharmacokinetics (PK) exposure by comprehensive profiling

cancer chemotherapy
cancer of the ovary
platinum-based chemotherapy
  • 27 views
  • 04 Oct, 2022
  • 9 locations
A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

resected Stage IIB-IIIB (early-stage) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC

chemoradiotherapy
cancer chemotherapy
adjuvant chemotherapy
atezolizumab
lung carcinoma
  • 1 views
  • 20 Oct, 2022
  • 40 locations
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA)

allocation to: Arm A: Sacituzumab govitecan (days 1, 8 q3w for eight cycles); Arm B: treatment of physician´s choice (TPC, defined as capecitabine or platinum-based chemotherapy for

breast-conserving surgery
BRCA1
invasive carcinoma
ki-67
BRCA1/2
  • 10 views
  • 28 Apr, 2022
  • 69 locations
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, …

  • 0 views
  • 24 Oct, 2022
  • 19 locations
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (TRIDENT-1)

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy …

cancer
solid tumor
ROS1
  • 369 views
  • 18 Oct, 2022
  • 146 locations